# UCB Raises 2026 Revenue Growth Guidance

> UCB updates 2026 revenue and EBITDA growth forecasts after strong BIMZELX and CIMZIA performance.
- Title: UCB Raises 2026 Revenue Growth Guidance · Pulse 2.0 | Shortify
- Summary: UCB updates 2026 revenue and EBITDA growth forecasts after strong BIMZELX and CIMZIA performance. UCB raised 2026 revenue growth to low-20% range and…
- Keywords: ucb, bimzelx, cimzia, revenue growth, ebitda growth, 2026, pharmaceuticals, immunology, startups, business, Raises, Revenue
- Source: Pulse 2.0 — https://pulse2.com/ucb-raises-2026-revenue-growth-guidance-to-low-20-range-and-adjusted-ebitda-growth-outlook-to-low-to-mid-40-range
- Author: Amit Chowdhry
- Published: 2026-10-22T16:28:57+00:00
- Read time: 1 min
- Topics: ucb, bimzelx, cimzia, revenue growth, ebitda growth, 2026, pharmaceuticals, immunology, startups, business
## UCB Updates 2026 Financial Guidance
UCB raised full-year 2026 revenue growth guidance to low-20% range at constant exchange rates.
## Adjusted EBITDA Growth Forecast Increased
UCB now expects adjusted ebitda growth in low-to-mid-40% range at constant exchange rates.
## BIMZELX Commercial Momentum
BIMZELX gains commercial traction in the united states with stronger prescription volumes and patient retention.
## CIMZIA Sustained Market Performance
CIMZIA maintains volume growth despite contraction in the broader anti-tnf treatment market.
## Improved Pricing Dynamics
BIMZELX shows more favorable net pricing dynamics in the united states with higher average revenue per patient.
## 2027 Financial Results Timeline
UCB will publish full-year 2026 financial results and 2027 guidance on february 25, 2027.
## Key takeaway

UCB raised 2026 revenue growth to low-20% range and adjusted EBITDA growth to low-to-mid-40% range due to BIMZELX and CIMZIA commercial success.